Insitro vs Karius

Side-by-side comparison of AI visibility scores, market position, and capabilities

Karius leads in AI visibility (73 vs 34)
Insitro logo

Insitro

EmergingBiotechnology

ML Drug Discovery

Drug discovery company founded by Daphne Koller integrating ML with high-throughput biology; raised $400M+ to build proprietary biological datasets for predicting drug targets and clinical outcomes in neurology, metabolic, and oncology programs.

AI VisibilityBeta
Overall Score
D34
Category Rank
#183 of 198
AI Consensus
77%
Trend
stable
Per Platform
ChatGPT
34
Perplexity
39
Gemini
36

About

Insitro is a drug discovery company founded in 2018 by Daphne Koller, a pioneer in machine learning and computational biology, having raised over $400M to build an integrated ML and biology platform. The company generates large-scale biological datasets using automated laboratory systems and human induced pluripotent stem cell models of disease, then trains machine learning models on this data to predict drug targets, patient stratification, and clinical outcomes. Unlike companies that apply ML to existing datasets, Insitro builds proprietary biological datasets specifically designed to train predictive models for drug discovery. The platform is being applied to neurological diseases, metabolic disorders, and oncology with the goal of identifying drug candidates more likely to succeed in clinical trials. Insitro has established partnerships with major pharmaceutical companies including Gilead Sciences and Bristol Myers Squibb to co-develop drugs using the platform. The company represents a model for how ML can be deeply integrated into pharmaceutical R&D rather than applied as a surface-level analytical layer.

Full profile
Karius logo

Karius

LeaderLife Sciences & BioTech

Genomic Infectious Disease Diagnostics

Karius raised $409M total including a $100M Series C in May 2024; its genomic blood test detects 1,000+ pathogens at 400+ U.S. hospitals; launched Karius Focus BAL for pneumonia in April 2025.

AI VisibilityBeta
Overall Score
B73
Category Rank
#12 of 198
AI Consensus
78%
Trend
stable
Per Platform
ChatGPT
69
Perplexity
70
Gemini
70

About

Karius is a Redwood City, CA-based life sciences company founded in 2014 that developed the Karius Test — a single blood draw that uses next-generation sequencing and AI to detect over 1,000 pathogens (bacteria, fungi, viruses, parasites) in seriously ill patients. The test is used when conventional cultures and targeted diagnostics fail, providing clinicians at transplant centers, children''s hospitals, and ICUs with a comprehensive pathogen report within 24 hours.

Full profile

AI Visibility Head-to-Head

34
Overall Score
73
#183
Category Rank
#12
77
AI Consensus
78
stable
Trend
stable
34
ChatGPT
69
39
Perplexity
70
36
Gemini
70
36
Claude
75
29
Grok
77

Key Details

Category
ML Drug Discovery
Genomic Infectious Disease Diagnostics
Tier
Emerging
Leader
Entity Type
brand
brand

Capabilities & Ecosystem

Capabilities

Only Insitro
ML Drug Discovery

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.